The technology under assessment is still in its early stage of development and evidence based answers to the AEs of SOC domain we selected during the protocol, cannot be given.
Lo Scalzo A et al. Result Card SOC2 In: Lo Scalzo A et al. Social aspects In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267